BHVN Stock: Price, Earnings History and SEC Filings
Biohaven Ltd. (BHVN) last traded at $15.42, down 6.49% on the latest session and up 15.5% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-0.86 against an analyst estimate of $-0.80, a miss of 7.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BHVN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-0.86 | $-0.80 | -7.50% |
| Jun 2026 | Aug 10, 2026 | $-0.91 | $-0.77 | -18.18% |
| Mar 2026 | May 4, 2026 | $-0.88 | $-0.86 | -2.33% |
| Dec 2025 | Mar 2, 2026 | $-1.21 | $-1.22 | +0.82% |
BHVN beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How BHVN reacts to earnings
Across its last 8 earnings releases, BHVN moved 4.3% on average the next session, in either direction. It rose after 1 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | -6.49% |
| 2026-08-10 | After close | -0.34% |
| 2026-05-04 | After close | -4.24% |
| 2026-03-02 | After close | -9.65% |
| 2025-11-10 | Before open | -5.69% |
| 2025-08-11 | After close | +0.45% |
| 2025-05-12 | After close | -5.11% |
| 2025-03-03 | After close | -2.15% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BHVN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$739M | -$610M | – | $-6.86 |
| 2024 | – | -$846M | -$587M | – | $-9.28 |
| 2023 | – | -$408M | -$335M | – | $-5.73 |
| 2022 | – | -$570M | -$304M | – | $-12.75 |
| 2021 | – | -$214M | -$147M | – | $-5.43 |
| 2020 | – | -$119M | -$77M | – | $-3.01 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BHVN
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 10-Q · Oct 29, 2026
- 8-K · Oct 22, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Oct 15, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 10, 2026Other events
- 8-K · Aug 26, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 10, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 10, 2026
- 8-K · Aug 7, 2026Officer or director change, Financial statements and exhibits
- 8-K · Jul 9, 2026Officer or director change, Financial statements and exhibits
Insider filing activity
BHVN insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BHVN news
- Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?Oct 30, 2026 · finance.yahoo.com
- Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsOct 29, 2026 · finance.yahoo.com
- Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to TradeOct 29, 2026 · finance.yahoo.com
- JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsightOct 26, 2026 · finance.yahoo.com
- Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous NephropathyOct 26, 2026 · finance.yahoo.com
- Biohaven Could Transform With Troriluzole's FDA Approval, RBC SaysOct 23, 2026 · finance.yahoo.com
- Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review AcceptanceOct 23, 2026 · finance.yahoo.com
- Biohaven’s Vyglxia NDA Resubmission Gains FDA ReviewOct 23, 2026 · theglobeandmail.com
About Biohaven Ltd.
Biohaven Ltd. (BHVN) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Virgin Islands British. Its fiscal year ends in December.